BUZZ - Morningstar maintains fair value estimate for Aurora Australiana due to strong performance in its canning business
路透社2026/10/15 22:26October 15 - ** Analysts at Morningstar have maintained a fair value estimate of AUD 2.3 for Orora Ltd (ORA.AX), which is above the previous trading day's closing price. The company's share price fell following Orora's (ORA) FY27 first-quarter trading update.
** The investment research firm predicts that FY27 adjusted EBIT will decline by 19% year-on-year due to falling sales in the Saverglass segment and rising manufacturing costs.
** Morningstar believes the market is impatient with Saverglass, a division that has faced major headwinds from US tariffs, cost-of-living pressures, and war in the Middle East.
** Market sentiment has also affected the outlook for Orora's can manufacturing business, though Morningstar considers this segment to have a potential moat.
** Orora is one of Australia's largest can manufacturers, and collaborates with Coca-Cola KO.N, Asahi 2502.T, and Suntory 2587.T.
** According to data compiled by LSEG (London Stock Exchange Group), out of 12 analysts, only one rates the stock a "buy" or higher, while 11 rate it as a "hold"; the median target price is AUD 1.57.
** As of the last close, the stock has fallen 38.9% so far this year.
(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of automated translations and provides them purely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.


Trump promotes the "manufacturing card" again for midterm elections: Audi to invest $4 billion in a U.S. plant, plans annual production of 200,000 SUVs
Audi plans to invest 4 billion dollars to build a factory in the United States, with an annual production capacity of 200,000 SUVs, creating 4,500 jobs. The German labor union criticized the CEO's supportive attitude as "puzzling," and the final decision will be made by the Volkswagen supervisory board.
